RxDoctor Payments Data

Aaron Winterstern, MD

Hospitalist · Jonesboro, ARNPI 1881034460

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by GSK at 32.1% of the total. Reporting peaked in 2024 at $167 and has fallen 90.6% since, to $16 in 2025.

$508in general payments, 2019–2025

Across 24 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$163
  • Boehringer Ingelheim$126
  • Novartis$79
  • Merck$50
  • Pfizer$41
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$508100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$508 in reported general payments places this provider in the 85th percentile of 125 hospitalist providers in Arkansas.

See all hospitalist providers in Arkansas

Medicare billing

Part B allowed, 2024
$305,266
Medicare patients
531
Services billed
2,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$14,848
JardianceEmpagliflozin17$11,046
EntrestoSacubitril/Valsartan12$6,032
BrilintaTicagrelor12$4,906
Divalproex Sodium11$849
Levetiracetam14$383
Furosemide81$372
Pantoprazole Sodium64$372
Cefdinir39$368
Potassium Chloride26$346
Lactulose17$279
Prednisone64$259
Amiodarone Hcl22$186
Metoprolol Tartrate49$186
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$14,84823 claims
Boehringer IngelheimJardiance$126$11,04617 claims
NovartisEntresto$79$6,03212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 125 hospitalist providers in Arkansas.

Other hospitalist in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →